Advances in engineered bacteria vaccines for enhancing anti-cancer immunity

Abstract

Advances in synthetic biology have enabled the development of tumor-targeted live bacterial therapeutics. In a recent study published in Nature, Redenti et al. engineered Escherichia coli Nissle 1917(EcNc^{Δlon/ΔompT/LLO+} nAg), which exploits the advantages of living medicines to deliver arrays of tumor-specific neoantigenic epitope in optimal environments, thereby providing a novel strategy for developing effective and durable cancer immunotherapies.

Keywords

Engineered bacteria / antitumor / neoantigenic / immunotherapy

References

[1] Duong MT,You SH.Bacteria-cancer interactions: bacteria-based cancer therapy.Exp Mol Med2019;51:1-15 PMCID:PMC6906302

[2] McNerney MP,Ng TL,Silver PA.Theranostic cells: emerging clinical applications of synthetic biology.Nat Rev Genet2021;22:730-46 PMCID:PMC8261392

[3] Gujrati V,Malekzadeh-Najafabadi J.Bioengineered bacterial vesicles as biological nano-heaters for optoacoustic imaging.Nat Commun2019;10:1114 PMCID:PMC6405847

[4] Mimee M,Hayward A.An ingestible bacterial-electronic system to monitor gastrointestinal health.Science2018;360:915-8 PMCID:PMC6430580

[5] Redenti A,Redenti B.Probiotic neoantigen delivery vectors for precision cancer immunotherapy.Nature2024;635:453-61 PMCID:PMC11560847

[6] Chen YE,Veinbachs A.Engineered skin bacteria induce antitumor T cell responses against melanoma.Science2023;380:203-10